UPDATE: Acasti Postpones Topline Results For TRILOGY 1 Phase 3 Trial Of CaPre From Dec. 2019 To Jan. 2020, Cites 'unexpected delay in data processing, transfer from central testing labs to statistical consultants for independent, external validation'